Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2016 -- G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that Chief Executive Officer Mark Velleca, MD, PhD, will present a company overview at the 18th Annual BIO CEO & Investor Conference. The presentation will take place on Tuesday, February 9 at 1:30 p.m. ET at the Waldorf Astoria New York in New York City.
For additional information on the conference, visit: http://www.bio.org/events/conferences/bio-ceo-investor-conference.
About G1 Therapeutics, Inc.
G1 Therapeutics is a clinical-stage oncology company developing novel, small-molecule therapies that address significant unmet needs in patients with cancer. The company is advancing G1T28, a first-in-class drug candidate, and G1T38, a potential best-in-class compound, in multiple oncology indications. G1 is privately held and based in Research Triangle Park, NC.
Visit www.g1therapeutics.com for more information.
Contact: Mark Velleca, MD, PhD G1 Therapeutics 919-213-9838 [email protected] Media: Laura Bagby 6 Degrees Communications 312-448-8098 [email protected]
